Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3633837

CC(C)Cc1c(N)cccc1Cl.N

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
TSHR P16473 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
NR4A2 P43354 1/20 0.41
CFTR P13569 1/20 0.38
CYP3A4 P08684 2/20 0.38
PIK3CA P42336 1/20 0.38
PARP1 P09874 1/20 0.37
PNMT P11086 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
AKR1B1 P15121 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27692325 0.83 PARP1 (0.43) ALDH1A1TSHRTAAR1CYP3A4PIK3CA
SCHEMBL5018858 0.83 TAAR1 (0.44) ALDH1A1TAAR1CFTRCYP3A4PNMT
SCHEMBL2399172 0.76 GABRA1 (0.52) TSHRTAAR1CYP3A4PIK3CAPARP1
SCHEMBL9911363 0.76 CFTR (0.40) ALDH1A1TAAR1CFTRCYP3A4PNMT
SCHEMBL3791097 0.75 ALDH1A1 (0.52) ALDH1A1TSHRTAAR1NR4A2CYP3A4
SCHEMBL29701394 0.75 ALDH1A1 (0.52) ALDH1A1TSHRTAAR1NR4A2CYP3A4
SCHEMBL11758388 0.74 TSHR (0.52) ALDH1A1TSHRTAAR1NR4A2CYP3A4
SCHEMBL23841326 0.74 CFTR (0.46) ALDH1A1TSHRTAAR1CFTRGAA
SCHEMBL15248195 0.74 CFTR (0.39) ALDH1A1TAAR1CFTRCYP3A4PNMT
SCHEMBL14485426 0.74 GABRA1 (0.50) ALDH1A1TSHRTAAR1CFTRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679299-A Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 NOVARTIS AG 2010-03-24 CN disclosed
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 ALDH1A1 45/4885TSHR 4209/4885TAAR1 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.